Alexion to acquire Boston-based Syntimmune in $1.2bn deal
Alexion acquisition of Syntimmune : US pharma company Alexion Pharmaceuticals has signed a deal of around $1.2 billion to acquire
Continue readingCoverage of Global Pharma Industry News
Alexion acquisition of Syntimmune : US pharma company Alexion Pharmaceuticals has signed a deal of around $1.2 billion to acquire
Continue readingTaro Pharmaceutical Industries said that it has scrapped its licensing agreement with Scottish biotech company NovaBiotics for Novexatin after the
Continue readingTrovagene, a California-based cancer research company, said that it has wrapped up the second dosing cohort of the Onvansertib-decitabine combination,
Continue readingLilly migraine drug Emgality FDA approval : Eli Lilly and Company (Lilly) has bagged approval from the US Food and
Continue readingSpanish pharma company Almirall has completed its $550 million acquisition of five skin medications from Allergan’s Medical Dermatology unit in
Continue readingJanssen Pharmaceutical Companies of Johnson & Johnson depression medication esketamine nasal spray did not meet expectations in a phase 3
Continue readingA seven-year study held in more than 19,000 older people from the US and Australia found that daily intake of
Continue readingRoivant Sciences has launched a new biopharma company named Respivant Sciences which will focus on developing innovative therapeutics for serious
Continue readingAjovy FDA approval : Israeli pharma company Teva Pharmaceutical Industries has bagged the US Food and Drug Administration (FDA) approval
Continue readingAllergan acquisition of Bonti : Irish pharma company Allergan will acquire Bonti, a US aesthetic company, engaged in the development
Continue reading